Bioanalytical and CMC Services for small molecules, biologics and
advanced therapies for the life science industry
The Kymos Group is an analytical CRO with three European laboratories devoted to providing bioanalytical and CMC services for the life science industry throughout the entire product life cycle: from early research and development to manufacturing and commercialization. We are GLP- and GMP-certified, have been successfully inspected by the EMA and the FDA and are experts in analytical and quality control work with small molecules, biologics and oligonucleotides. Kymos provides services to clients worldwide in the pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic and nutraceutical industries.
Testimonials
“We are currently developing multiple new biosimilar projects and consider Kymos one of the best CROs in Europe for drug release and testing.”
“We were positively impressed when Kymos reacted to our needs by investing in their stability capabilities, and now, two years down the line, with projects in full-swing, I can safely say that we made the right choice. In Kymos we have found a reliable, committed, trustworthy and professional partner.”
“Back in 2017 there weren’t many analytical CROs able to carry out Franz cell assays and Kymos’ pioneering work was pivotal for the registration of our product.”
“Kymos offered superior historical expertise by being exposed to so many different clients, pharmacological compounds, and therapeutic areas. They addressed and anticipated very diverse problems.”
“I have had a long and fruitful experience with Kymos and have a huge interest in their participation owing to their reliability.”
“Prolytic is our analytical partner throughout the entire drug development process. Such a long and complex process requires a laboratory you can trust. Professional yet flexible, Prolytic accompanies us through the preclinical and clinical phases.”
“Establishing robust miRNA methods for valuable results is tricky. The team at Prolytic have been a key collaboration partner. With their 30 years of experience in bioanalytics and broad know-how in different techniques, study types, and substance groups, we were able to quickly develop a reproducible and reliable analysis method for miRNAs.”
Latest News
miRNA Analysis: From Fundamental Research to Product Innovation
The Nobel Prize in Medicine for 2024 brings long-awaited recognition to a once-overlooked molecule: microRNA, or miRNA. This year, the prize is awarded to scientists and researchers Victor Ambros and Gary Ruvkun for the discovery (...) Read more
ICH M10 Comparison with EMA and FDA Past Guidelines on Bioanalytical Method Validation
Although the ICH has published recommendations for the validation of analytical methods used in the evaluation of the quality of drugs and active substances (ICH Q2) for more than 25 years, it was not until (...) Read more
KOREA PHARM & BIO: Goyang, KR | 23-26 Apr 2024
BIO KOREA 2024: Seoul, KR | 08-10 May 2024
BIO International Convention: San Diego, US | 3-6 Jun 2024
Congrès POLEPHARMA Biotesting: Évreux, FR | 5-6 Jun 2024
AFI Symposium: Rimini, IT | 5-7 Jun 2024
BIOPLUS – INTERPHEX KOREA: Seoul, KR | 10-12 Jul 2024
Farmaforum: Madrid, ES | 25-26 Sep 2024
Biomarkers Europe 2024: Basel, CH | 30 Sep – 01 Oct 2024
CPHI 2024: Milan, IT | 8-10 Oct 2024
European Bioanalysis Forum: Barcelona, ES | 20-22 Nov 2024
PharmaLab Congress: Düsseldorf, DE | 25-27 Nov 2024
I4ID 2024: Lyon, FR | 27-28 Nov 2024
